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Abstract 
Nanoparticles formulated from biodegradable polymers like poly(lactic-co-glycolic acid) (PLGA) are being extensively 
investigated as drug delivery systems due to their two important properties such as biocompatibility and controlled 
drug release characteristics. The aim of this work to formulated diazepam loaded PLGA nanoparticles by using emul-
sion solvent evaporation technique. Polyvinyl alcohol (PVA) is used as stabilizing agent. Diazepam is a benzodiaz-
epine derivative drug, and widely used as an anticonvulsant in the treatment of various types of epilepsy, insomnia 
and anxiety. This work investigates the effects of some preparation variables on the size and shape of nanoparticles 
prepared by emulsion solvent evaporation method. These nanoparticles were characterized by photon correlation 
spectroscopy (PCS), transmission electron microscopy (TEM). Zeta potential study was also performed to understand 
the surface charge of nanoparticles. The drug release from drug loaded nanoparticles was studied by dialysis bag 
method and the in vitro drug release data was also studied by various kinetic models. The results show that sonication 
time, polymer content, surfactant concentration, ratio of organic to aqueous phase volume, and the amount of drug 
have an important effect on the size of nanoparticles. Hopefully we produced spherical shape Diazepam loaded PLGA 
nanoparticles with a size range under 250 nm with zeta potential −23.3 mV. The in vitro drug release analysis shows 
sustained release of drug from nanoparticles and follow Korsmeyer-Peppas model.
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Release kinetic models
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1  Background
Nanotechnology defines the study and production of 
structures and devices on a nanoscale range. Nanoparti-
cles have been extensively studied by researchers in bio-
medical and biotechnological areas, especially in drug 
delivery systems, because their particle size they have the 
potential to increase drug stability, improve its duration 
of therapeutic effect and reduce its degradation metabo-
lism as well as cellular uptake [1]. Preparation and char-
acterization of nanoparticles are today’s an important 
task for researchers, as selection of size and shape of 
nanoparticles provides a capable control over many of 
the physical and chemical properties [2]. Different mate-
rials can be used to form these nanoparticles such as pol-
ymers, lipids, natural biopolymer etc., but biodegradable 
and biocompatible polymers have been widely used for 
the preparation of polymeric nanoparticles [3].
Poly(D,L-lactide-co-glycolide) (PLGA) polymers, have 
attracted significant interest for delivery systems because:
  • They are biocompatible, biodegradable and less toxic 
[4].
  • Approved by the FDA (US Food and Drug Adminis-
tration) [5].
  • The exclusive structure of PLGA nanoparticles, com-
posed of a hydrophilic surface and a hydrophobic 
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core, provides a drug carrying reservoir and also ena-
bles them to dissolve in aqueous solutions [6].
  • The by-products of PLGA are the lactic acid and gly-
colic acid, can be excreted from the body as water 
and carbon-dioxide through the tricarboxylic acid 
cycle [7, 8].
  • The most remarkable one is probably the carrier 
delivery system that encapsulates active ingredients 
and releases them under a controlled mechanism [9].
Various methods are proposed for the preparation of 
drug loaded PLGA nanoparticles such as an emulsion sol-
vent evaporation method [10], nanoprecipitation method 
[11], double emulsion solvent evaporation method [12] 
etc. Many stabilizers are used to prevent the aggregation 
of these nanoparticles [13] and different organic solvents 
are used to dissolve the polymer and drug [14].
Diazepam is a lipophilic benzodiazepine derivative 
drug. Benzodiazepines are considered the treatment of 
choice for acute management of cruel seizures. Benzodi-
azepines are active against a wide range of seizure types, 
have a rapid onset of action once delivered into the cen-
tral nervous system, and are safe [15]. The IUPAC name 
of diazepam is 7-chloro-1,3-dihydro-1-methyl-5- phenyl-
1,4-benzodiazepin-2(3H)-one, it is widely used as an anti-
convulsant in the treatment of various types of epilepsy, 
insomnia, anxiety and for induction and maintenance of 
anesthesia [16]. Figure 1 shows the chemical structure of 
diazepam.
Diazepam could be administered via different routes: 
orally, intravenous injections, rectal solutions, rectal gels, 
and suppositories [17]. Generally, oral administration of 
Diazepam is the route of choice in the daily practice of 
pharmacotherapy. However, abuse of diazepam can have 
serious consequences, even causing death when taken in 
overdose [18].
On the basis of literature reviewed, it was found that 
several authors reported the preparation of Diazepam 
loaded nanoparticles with different method by using dif-
ferent stabilizer, but none of them previously reported 
the preparation and optimization of PLGA nanoparticles 
containing Diazepam by emulsion-solvent evaporation 
method by using PVA as stabilizer.
The aim of the work to report here was to design and 
characterize Diazepam-loaded PLGA nanoparticles in 
order to obtain a controlled release system. Nanoparti-
cles were prepared by the emulsion solvent evaporation 
method and characterized the formulation in terms of 
size, morphology, drug encapsulation and drug release. 
This work also investigated the effect of different prepa-
ration variables such as sonication time, polymer con-
tent, organic phase volume to aqueous phase volume 
ratio, surfactant content and amount of drug. The in vitro 
drug release and the drug release data of drug loaded 
nanoparticles was studied by dialysis bag method and 
various kinetic models respectively. The significance of 
this work is to explain the effect of different parameters 
scientifically which are responsible to control the size of 
nanoparticles prepared by this method.
2  Methods
2.1  Materials
The biodegradable polymer studied was PLGA 
(RESOMER® RG 504 molecular weight range is 38,000–
54,000 and inherent viscosity is 0.45–0.60  dl/g) with a 
copolymer ratio of dl-lactide to glycolide of 50:50 gifted 
from Evonik Mumbai (India). The surfactant used in this 
process was polyvinyl alcohol (PVA) purchased from 
Sigma-Aldrich, Mumbai (India). Diazepam was received 
as gift sample from Windlas Biotech Ltd, Dehradun 
(India). Purified water of Milli-Q quality was used to pre-
pare the solutions as well as the aqueous phases of the 
emulsions. All other reagents were of analytical grade.
2.2  Preparation of diazepam loaded nanoparticles
The diazepam loaded nanoparticles were prepared by 
an emulsion solvent evaporation method [10]. Typically, 
known amounts of mass of PLGA polymer and diaz-
epam were added into ethyl-acetate, which was suitably 
stirred to ensure that all material was properly dissolved 
in solvent. Then, the solution of organic phase was slowly 
poured into the stirred aqueous solution of PVA. This 
mixture was sonicated using a microtip probe sonica-
tor energy output of 55 W in a continuous mode (Soni-
weld Probe Sonicator, Imeco Ultrasonics, India) for a few 
minutes. The formed oil in water (O/W) emulsion was 
gently stirred at room temperature by a magnetic stirrer 
(Remi, India) for 5  hours to evaporate the organic sol-
vent. The nanoparticles were recovered by centrifugation 
(22,000 rpm, 25 min; WX ultra 100 ultracentrifuge Ther-
mofisher Scientific USA) and washed with distilled water 
2–3 times to remove the surfactant. The purified nano-
particles were freeze-dried (YSI-250, Yorco Freeze Dryer 
(Lyophilizer), Yorco Sales Pvt. Ltd., India) to obtain the 
fine powder of nanoparticles, which was placed and kept 
in vacuum desiccators.Fig. 1 Chemical structure of Diazepam
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2.3  Nanoparticles characterization
The size (Z-average mean) and zeta potential of the 
nanoparticles were analyzed by photon correlation spec-
troscopy (PCS) or dynamic light scattering (DLS), respec-
tively, in triplicate using a Zetasizer (Model- ZEN 3600, 
Malvern Instruments, U.K.). The dried powder samples 
were suspended in distilled water and slightly sonicated 
before analysis. The obtained homogeneous suspension 
was measured for the volume mean diameter and size 
distribution. Each measurement was done in triplicate. 
The shape, surface morphology and size analysis of the 
nanoparticles were analyzed by transmission electron 
microscopy (TECNAI 200 kV TEM (Fei, Electron Optics) 
Japan). A droplet of the nanoparticles was placed on a 
carbon-coated copper grid, forming a thin liquid film. 
The negative staining of samples was obtained with a 2 % 
(w/V) solution of phosphotungstate acid.
2.4  Entrapment efficiency
Nanoparticles were separated from dispersion by cen-
trifugation at 22,000  rpm for 25  min. The supernatant 
obtained after centrifugation was suitably diluted and 
analyzed for free diazepam by UV–Visible spectropho-
tometer (Model No.-2201, UV–visible double beam 
spectrophotometer, Shimadzu, India) at 325 nm. The per-
centage entrapment efficiency was calculated as:
2.5  In‑vitro drug release
The in-vitro drug release study of diazepam loaded PLGA 
nanoparticles formulations were studied by dialysis bag 
diffusion method [19]. Drug loaded nanoparticles (5 ml) 
were dispersed into dialysis bag and the dialysis bag was 
then kept in a beaker containing 100 ml of pH 7.4 phos-
phate buffer. The beaker was placed over a magnetic 
stirrer and the temperature of the assembly was main-
tained at 37 ±  1  °C throughout the experiment. During 
the experiment rpm was maintained at 100 rpm. Samples 
(2  ml) were withdrawn at a definite time intervals and 
replaced with equal amounts of fresh pH 7.4 phosphate 
buffer. After suitable dilutions the samples were analyzed 
using UV–Visible spectrophotometer at 325 nm.
To analyze the in vitro drug release data various kinetic 
models were used to describe the release kinetics. The 
zero order rate Eq.  (2) explains the systems where the 
rate of drug release does not depend on its concentra-
tion [20]. The first order Eq.  (3) explains the release 
from the system where rate of drug release is concentra-
tion dependent [21]. Higuchi [22] described the release 
of drugs from insoluble matrix as a square root of time 
(1)
% Entrapment efficiency = [Drug]total − [Drug]supernant
[Drug]total
× 100
dependent process based on Fickian diffusion Eq.  (4). 
Korsmeyer et al. [23] derived a simple mathematical rela-
tionship which described the drug release from a poly-
meric system Eq. (5).
where, C is the concentration of drug at time t, t is the 
time and k0 is zero-order rate constant expressed in units 
of concentration/time.
where, C0 is the initial concentration of drug and k1 is the 
first order rate constant.
 
where, KH is the constant reflecting the design variables 
of the system.
where Mt/M∞ is the fraction of drug released at time t, 
KKP is the rate constant and n is the release exponent.
3  Results and discussion
3.1  Effect of different preparation variables on formulation 
characteristics
By using the emulsion solvent evaporation technique, 
several process parameters were tested to achieve best 
preparation conditions, including time of sonication, 
amount of polymer in the formulation, surfactant con-
tent in the formulation, organic to aqueous phase vol-
ume ratio and diazepam content. Only one factor was 
replaced in each series of experiments.
3.1.1  Effect of sonication time
In emulsion solvent evaporation technique the fundamen-
tal step is the addition of energy to obtain the emulsion 
and it is provided by sonication. To explain the influ-
ence of sonication time on nanoparticles shape and size, 
it was varied from 1 to 5 min. The preparation procedure 
yielded spherical particles in all cases according to TEM 
results. It can be concluded that on increasing the sonica-
tion time (from 1 to 5 min) the applied energy increases, 
so this leads to a decrease in the size of nanoparticles 
(from 430 to 265  nm), these results are summarized by 
in Fig.  2 by graph (a) and TEM image for nanoparticles 
prepared by 5 min sonication in shown in Fig. 3 by image 
(a). The emulsification can be considered one of the most 
significant steps of this technique, because the formation 
of large particles is the outcome of an insufficient disper-
sion of phases. Our results are in accordance with those 
observed by other authors [24, 25]. 
(2)C = kot
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3.1.2  Effect of PLGA content
To verify the influence of the effect of polymer content, it 
was varied between 10 to 20 mg/ml of organic phase, and 
the effect of the initial amount of polymer on the parti-
cles morphology and size were studied. The results are 
concluded by graph (b) in Fig. 2.
According to TEM results nanoparticles prepared with 
different amount of polymer are spherical in shape, but on 
increasing the polymer content lead to a regular increase 
in nanoparticles diameter. When the amount of PLGA 
was doubled from 10 to 20 mg/ml of organic phase, the 
particle diameter increased from 270 to about 390  nm. 
In Fig. 3 image (b) exhibits the TEM image of nanoparti-
cles prepared by using the PLGA as 10 mg/ml of organic 
phase. According to this result, it can be conclude that, for 
this technique the polymer content in the organic phase 
is a significant factor, because the size of nanoparticles 
increased as polymer concentration was increased. The 
increase in the particle size with an increase in polymer 
amount was reported by other authors [26, 27]. This was 
probably caused by the increasing viscosity of dispersed 
phase (organic phase), resulting a low dispersability of 
the PLGA solution into the aqueous phase. Increase in 
polymer concentration leads to an increase in the vis-
cous forces resisting the droplet break down by sonica-
tion. These forces oppose the shear stresses in the organic 
phase and the final size of particles depends on the net 
shear stress, which is available for droplet breakdown [24].
3.1.3  Effect of organic phase volume to aqueous phase 
volume ratio
The ratio of organic phase and aqueous phase of an emul-
sion is an important factor in this technique. The organic 
volume was varied among 1–5  mL by keeping constant 
the aqueous phase volume, and its effect on nanoparti-
cles size was observed and summarized in graph (c) in 
the Fig. 2 and TEM result by image (c) in Fig. 3. From the 
results it was observed that an increase in the organic/
Fig. 2 Effect of a sonication time on the size of nanoparticles b PLGA content in organic phase in mg/ml on the size of nanoparticles c volume of 
organic phase in ml on the size of nanoparticles d volume of PVA content in  %w/V of aqueous phase and e diazepam content in mg/ml of organic 
phase
Fig. 3 TEM image for nanoparticles prepared by a 5 min sonication b 10 mg/ml PLGA of organic phase c 5 ml of organic solvent d 1 % (w/V) PVA of 
aqueous phase and e 1.5 mg/ml diazepam of organic phase (or optimization o different variables)
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aqueous ratio leads to decrease of the size of nanoparti-
cles from 430 to 345 nm. This occurs due to the coales-
cence of droplets can be prevented by a large amount of 
organic solvent available for diffusion in the emulsion.
3.1.4  Effect of PVA content
To study the effect of PVA content on the nanoparti-
cles, the aqueous phase with different PVA content (0.6 
to 1.2  % w/V) was prepared. It can be noticed that as 
the PVA content is increased, the diameter of nanopar-
ticles, first decreases and then gradually increases, the 
results are shown in graph (d) in Fig. 2 and TEM image 
(d) in Fig. 3. The presence of PVA molecules stabilizes the 
emulsion nanodroplets and prevents them from aggre-
gation with one another. For a better stabilization, the 
surfactant molecules must cover the organic/aqueous 
interfacial area of all the droplets. Hence a lowest amount 
of PVA molecules is required to achieve small size of 
nanoparticles. As the concentration of PVA is increased, 
the size of particles produced by this method decreases 
and then increases due to the increased viscosity of the 
aqueous phase; the viscosity increase reduces the net 
shear stress available for droplet breakdown (which is 
already discussed in “Effect of PLGA content” section). 
So the size decreases due to enhanced interfacial stabi-
lization whiles it increases due to the increased aqueous 
phase viscosity. The amount of surfactant plays an impor-
tant role in this technique [28, 29].
3.1.5  Effect of diazepam content
In this section the effect of diazepam into PLGA nano-
particles was examined. Maintaining constant all other 
formulation variables, the amount of diazepam used 
was varied 1.5 to 2.5 mg/ml of organic solvent. It can be 
concluded that the increase in the initial amount of drug 
increases the size of nanoparticles from 230 to 310 nm; 
Fig. 4 a DLS image and b Zeta potential graph for nanoparticles prepared by optimization of different variables
Fig. 5 In-vitro drug release for nanoparticles prepared by optimiza-
tion of different variables
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results are summarized by graph (e) in Fig.  2. This can 
be explained by the fact that a greater amount of drug 
results in a more viscous organic phase (dispersed phase), 
making complex the mutual dispersion of the phases and 
forming bigger nanoparticles. TEM experiments showed 
that the particles remained with a spherical shape in 
all cases, in Fig.  3 image (e) shows the TEM picture of 
nanoparticles prepared by drug in amount 1.5 mg/ml of 
organic solvent.
On the basis of the above discussion optimized diaz-
epam loaded-PLGA nanoparticles were successfully 
prepared in the size range 230 nm. For this purpose, opti-
mized variables are as: PLGA 10 mg/ml of organic phase, 
PVA 1 % w/V of aqueous phase, 5 ml of ethyl-acetate was 
used as organic solvent, diazepam used as 1.5 mg/ml of 
organic phase and sonication time was 5  min. By this 
optimized formulation we had got spherical nanopar-
ticles with a size range in 230  nm and zeta potential as 
−23.3 mV and drug entrapment efficiency as 66 %. TEM 
image of these nanoparticles is shown in Fig.  3(e), zeta 
size image and zeta potential of these nanoparticles in 
Fig. 4.
3.2  In‑vitro drug release
In-vitro  drug diffusion studies were carried out using 
dialysis bag method. The data of percentage drug release 
formulation were shown in Fig. 5. For kinetic study fol-
lowing plots were made: cumulative   % drug release vs. 
time (zero order kinetic model); log cumulative % drug 
remaining vs time (first order kinetic model); cumu-
lative   % drug release vs square root of time (Higuchi 
model); log cumulative  % drug release vs log time (Kors-
meyer–Peppas model). All Plots are shown in Fig. 6 and 
results are summarized in Table 1. In the above table R2 is 
correlation value, k is rate constant and n is release expo-
nent. On the basis of best fit with the highest correlation 
(R2) value it is concluded that in the optimized formula-
tion of nanoparticles follow the Korsmeyer-Peppas model 
with release exponent value n = 0.61. The magnitude of 
the release exponent n indicates the release mechanism is 
non Fickian diffusion.  
4  Conclusions
From the above investigation, we can conclude that the 
preparation of drug loaded nanoparticles by emulsion 
solvent evaporation method is governed by different 
Fig. 6 Drug release kinetics plots: a Zero order plot b First order plot c Higuchi plot and d Korsmeyer Peppas plot
Table 1 Interpretation of  R-square values and  rate con-
stants of release kinetics of nanoparticles
Model R2 K n
Zero order 0.729 1.1308 × 10−1 –
First order 0.773 3.9216 × 10−1 –
Higuchi 0.903 1.2588 –
Korsmeyer-Peppas 0.948 1.5848 × 10−4 0.61
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preparation variables. By the systematic study of these 
variables, we got the valuable results. In this technique 
the most important factor for reducing the size of nan-
oparticles is increase the shear stress during emulsifica-
tion, which is done by increasing the applied energy, 
decreasing the polymer content in organic solvent, 
using the sufficient amount of surfactant, increasing the 
organic phase volume to aqueous phase volume ratio. On 
the basis of optimization of these variables we have suc-
cessfully synthesized the spherical nanoparticles of diaz-
epam which are reproducible.
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